No, she should not take phentermine
This patient with a history of topiramate-induced acute angle-closure glaucoma should avoid phentermine, even as monotherapy. While topiramate is the primary culprit in the combination phentermine/topiramate ER, emerging evidence demonstrates that phentermine alone can independently cause acute angle-closure glaucoma through similar mechanisms.
Key Evidence Against Phentermine Use
The 2016 AACE/ACE Obesity Guidelines explicitly state that phentermine/topiramate ER should be avoided in patients with glaucoma 1. While this recommendation addresses the combination product, the guideline notes that phentermine/topiramate ER is contraindicated in patients with a history of glaucoma, with topiramate implicated in multiple case reports of acute-onset glaucoma 1.
Critical new evidence shows phentermine monotherapy can cause angle closure: A 2026 case report documented bilateral acute angle-closure glaucoma in a patient who discontinued topiramate after only 2 days but continued phentermine alone 2. More than one week after topiramate cessation, she developed IOPs of 55 and 53 mm Hg with complete 360° angle closure and bilateral choroidal effusions—the same mechanism seen with topiramate. This temporal relationship strongly implicates phentermine as an independent causative agent.
Mechanism of Risk
Both topiramate and phentermine can cause non-pupillary block angle closure through:
- Ciliochoroidal effusion
- Anterior displacement of the lens-iris diaphragm
- Shallow anterior chambers
- Appositional angle closure
The FDA label for topiramate warns that secondary angle-closure glaucoma typically occurs within 1 month of initiating therapy and requires rapid discontinuation 3. Your patient's recent topiramate-induced episode indicates she has demonstrated susceptibility to this mechanism.
Safer Alternatives
Preferred weight-loss medications for patients with glaucoma history 1:
- Liraglutide 3.0 mg (no known glaucoma association)
- Orlistat (no known glaucoma association)
- Lorcaserin (no known glaucoma association, though withdrawn from US market in 2020)
- Semaglutide 2.4 mg (GLP-1 agonist like liraglutide, preferred based on magnitude of weight loss) 4, 5
Use with caution:
- Naltrexone ER/bupropion ER should be used with caution in glaucoma patients 1, though it has less direct ocular risk than phentermine
Clinical Pitfalls to Avoid
Don't assume phentermine is safe just because topiramate was the initial trigger - The 2026 case report demonstrates phentermine's independent risk 2
Don't perform laser peripheral iridotomy (LPI) - This is a pupillary-block treatment and is ineffective for medication-induced effusion-related angle closure 6. The key interventions are drug cessation and cycloplegia.
Avoid acetazolamide if angle closure recurs - One case showed acetazolamide worsened topiramate-induced angle closure 7, likely due to its carbonic anhydrase inhibitor properties shared with topiramate
Monitor for cardiovascular effects - Phentermine carries additional risks including cardiomyopathy and valvulopathy, particularly with prolonged use 8
Bottom Line
Given this patient's demonstrated susceptibility to medication-induced angle closure from topiramate, phentermine poses an unacceptable risk even as monotherapy. The mechanism of choroidal effusion and anterior displacement can occur with phentermine alone 2. Choose GLP-1 receptor agonists (semaglutide or liraglutide) or orlistat instead, which have no known association with glaucoma and superior efficacy profiles 1, 4, 5.